Q2 momentum returns after tariff hit in Q1: what Oxford Instruments just told the market
Oxford Instruments’ interim trading update paints a tale of two quarters. Q1 was dented by tariffs and a jittery macro backdrop, but Q2 improved meaningfully. Management now expects full year revenue and adjusted operating profit to be broadly similar to last year on an organic constant currency basis.
In plain English: the business has stabilised after an early wobble, with a stronger second half set-up supported by a growing order book.
Headline takeaways for retail investors
- Group H1 order intake up just over 1% on an organic constant currency (OCC) basis, with Q1 down around 3% and Q2 up nearly 6%.
- Book-to-bill (orders divided by revenue) about 1.1 vs 1.0 last year – backlog building into H2.
- H1 revenue expected down around 8% OCC (down 10% reported) due to the Q1 dip.
- OCC adjusted operating margin around 14.5% in H1 (13.5% reported), with a “substantially stronger” H2 margin expected.
- On a reported basis, H2 revenue expected to be marginally up year-on-year.
- Full year OCC revenue, adjusted operating profit (AOP) and AOP margin now expected to be similar to prior year.
- Currency headwind increased by approximately £1 million on top of earlier £4.5 million guidance.
- Sale of the NanoScience business expected to complete in Q3 – results here focus on continuing operations.
Prior-year continuing operations for context (unaudited)
Oxford Instruments provided pro-forma FY25 numbers for continuing operations (excluding NanoScience). These are unaudited and for guidance only, but useful context for scale and margins:
| H1 FY25 | H2 FY25 | FY25 | |
|---|---|---|---|
| Imaging & Analysis revenue | £153.8m | £176.5m | £330.4m |
| Advanced Technologies revenue | £50.4m | £61.5m | £111.9m |
| Total revenue | £204.2m | £238.0m | £442.2m |
| Adjusted operating profit | £35.9m | £43.8m | £78.6m |
| Adjusted operating margin | 17.2% | 18.3% | 17.8% |
Imaging & Analysis: tariffs bit in Q1, Q2 stabilised
The Imaging & Analysis (I&A) division felt the brunt of tariff disruption and global uncertainty. Orders fell 11% in Q1, with Q2 flat year-on-year, leaving H1 I&A orders down around 6% OCC. H1 I&A revenue was around 9% lower OCC (down nearly 11% reported).
To their credit, the team re-priced most of the US open order book as tariff policy evolved, which helped protect profitability. They have also adapted manufacturing and supply chains and navigated rare earths supply challenges. That agility matters – it reduces the risk of long-term margin leakage from sudden policy shifts.
Management calls out Belfast as a key margin swing factor. Workforce reductions, a tighter product set and a renewed focus on OEM partnerships are already in place and expected to materially lift H2 margins. The wildcard is end-market demand: healthcare and life sciences recovery remains uncertain and conditions are “challenging”. In other words, cost actions are under Oxford’s control; the top line in these niches is not.
Advanced Technologies: compound semiconductor demand powering ahead
Advanced Technologies (AT) continues to be the bright spot. Orders grew 25% in Q1 and 26% in Q2, putting H1 orders up 25% OCC with a full order book for H2. The demand mix is attractive too – augmented reality and datacomms – with more orders from major commercial players for volume manufacturing.
Despite strong orders, AT H1 revenue is expected to be around 7% lower OCC (8% reported) due to two timing factors: tariff-related delays on shipments to China from the US X-Ray business, and a handful of high-value compound semiconductor systems slipping into Q3. That is more about timing than demand – the order book says the revenue should convert in H2.
The move to the new Severn Beach facility is complete and, crucially, is boosting customer confidence and opportunity generation. Facilities matter in deep tech – they are part of the sales pitch as well as capacity enablers.
Margins, FX and the full-year outlook: why guidance is sensible
Group H1 OCC AOP margin of about 14.5% is down on the FY25 profile, reflecting lost I&A revenue carry a high contribution margin. Management expects a “substantially stronger” H2 margin, supported by: modest revenue growth returning, normal seasonality, Belfast cost savings, and other margin initiatives. On a reported basis, H2 revenue should be marginally up year-on-year.
Full-year guidance is now for revenue, AOP and AOP margin to be similar to the prior year on an OCC basis. Given the book-to-bill of around 1.1 and the AT order strength, that looks achievable, with the main watch-outs being the tariff environment and healthcare/life sciences demand. Currency is a drag – an extra £1 million headwind on top of £4.5 million previously guided is now embedded in expectations.
Why this update matters for the investment case
- Evidence of momentum returning: Q2 orders up nearly 6% after a soft Q1 suggests the trough is likely behind the Group.
- Quality of demand improving: AT’s shift towards volume manufacturing with major commercial customers is strategically positive.
- Backlog support into H2: a book-to-bill of about 1.1 indicates revenue support and margin leverage in the second half.
- Cost actions bearing fruit: Belfast restructuring and portfolio focus should lift H2 margins, even if end-market recovery is slow.
- Near-term risks remain: tariffs can still disrupt shipments and customer decision-making, and healthcare/life sciences demand is uncertain.
Key definitions and a quick jargon buster
- Organic constant currency (OCC): growth excluding M&A/divestments and measured using last year’s exchange rates, including the effect of hedging.
- Adjusted operating profit (AOP): operating profit excluding amortisation/impairment of acquired intangibles, acquisition and reorganisation items, significant non-recurring items, and mark-to-market on derivatives.
- Book-to-bill: orders divided by revenue. Above 1.0 usually means backlog is increasing.
What to watch next
- Conversion of AT’s strong order book in H2, including delivery of the delayed high-value systems in Q3.
- H2 margin trajectory, particularly the scale of Belfast-driven uplift in I&A.
- Tariff policy developments and any impact on US-China shipments and pricing.
- Healthcare and life sciences demand stabilisation in I&A – any signs of recovery would be a bonus.
- FX sensitivity – how the £5.5 million total headwind (including the additional £1 million) tracks versus hedging.
- Completion of the NanoScience sale in Q3 and any subsequent portfolio simplification benefits. Proceeds and detailed terms are not disclosed here.
- Interim results on 11 November 2025 for fuller financials and outlook detail.
My take: cautious near term, constructive medium term
This is a sensible reset. Management is not banking on a full H1 recovery, but Q2 order momentum, a rising book-to-bill and tangible cost actions underpin a stronger H2. AT’s structural growth in compound semiconductors is the engine; I&A needs stable macro and a steadier healthcare market to re-accelerate.
Net-net, a stable full year on OCC after tariff turbulence is a respectable outcome. If H2 delivery is clean and NanoScience completes on schedule, the set-up for the following year could look meaningfully better, especially if order strength in AT keeps compounding.
